What This Means For You
The confrontation between DOMA Perpetual Capital Management and Pacira BioSciences highlights the growing power of activist investors to reshape the direction of major pharmaceutical companies. With Pacira generating $372 million in annual revenue and Exparel serving as a key non-opioid alternative for pain management, any forced sale or leadership change could impact drug pricing, research priorities, and patient accessThis case underscores the urgent need for transparency and accountability in executive compensation and board oversight, especially as activist campaigns become more frequent and aggressive. For investors, patients, and policymakers, the outcome will set a precedent for how much influence activist funds can exert over critical healthcare assets.